July 19, 2005 While waiting for the earnings announcement from Amgen, biotech moved cautiously higher today, managing to close with a small gain. The Centient Biotech 200 gained 7 points to end at 3602.21, a rise of .19%. After the closing bell, Amgen soared $4.63 or 6.6% following release of higher Q2 earnings, Roche paid $180 million for a Swiss biotech called GlycArt, Gilead and Royalty Pharma made a one-time payment of $525 million to Emory University to buy the royalty stream for Emtriva, Sosei of Japan paid $187 million for Arakis of the UK, Aptuit bought three divisions of Quintiles for $125 million, Able filed Chapter 11, and Vertex won fast-track for a new HIV protease inhibitor. More details...
